| Id: | acc1138 |
| Group: | 2sens |
| Protein: | c-Raf |
| Gene Symbol: | MYC |
| Protein Id: | P01106 |
| Protein Name: | MYC_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser259 |
| Site Sequence: | PEPLVLHEETPPTTSSDSEEE |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | Hep3B |
| Disease Info: | |
| Drug: | vitamin K1 + sorafenib |
| Drug Info: | "Sorafenib is an oral multikinase inhibitor developed by Bayer Pharmaceuticals, approved by the FDA in 2005, and used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine-refractory differentiated thyroid cancer. Vitamin K1: - " |
| Effect: | modulate |
| Effect Info: | "The combined use of vitamin K1 and sorafenib enhances the phosphorylation of c-Raf at Ser-43 and Ser-259 sites. It also promotes the phosphorylation of c-Met at Tyr-1349 site, thereby enhancing the inhibitory effect on the growth of tumor cells." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 21734462 |
| Sentence Index: | 21734462_9-10 |
| Sentence: | "Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth." |
Sequence & Structure:
MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MYC-Ser176 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser362 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.131 | ||||
| COAD | -0.769 | ||||
| HGSC | -0.362 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser363 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser76 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.857 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.134 | ||||
| GBM | 1.257 | ||||
| HNSC | 0.736 | ||||
| LUAD | -0.146 | ||||
| LUSC | -0.348 | ||||
| non_ccRCC | |||||
| PDAC | -0.678 | ||||
| UCEC | 0.902 | ||||
| MYC-Ser77 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser78 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser79 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser85 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.711 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.963 | ||||
| GBM | 1.12 | ||||
| HNSC | 0.547 | ||||
| LUAD | 0.557 | ||||
| LUSC | 0.268 | ||||
| non_ccRCC | |||||
| PDAC | -1.693 | ||||
| UCEC | 0.875 | ||||
| MYC-Thr72 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.784 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.003 | ||||
| GBM | 0.708 | ||||
| HNSC | 0.829 | ||||
| LUAD | 0.713 | ||||
| LUSC | -0.945 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.475 | ||||
| MYC-Thr73 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser1624 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.752 | ||||
| HGSC | 1.135 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.383 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser178 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.144 | ||||
| HGSC | |||||
| ccRCC | -0.849 | ||||
| GBM | 1.719 | ||||
| HNSC | -0.67 | ||||
| LUAD | -0.863 | ||||
| LUSC | -0.269 | ||||
| non_ccRCC | 1.225 | ||||
| PDAC | -0.948 | ||||
| UCEC | 0.798 | ||||
| MYCBP2-Ser181 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.869 | ||||
| COAD | -0.244 | ||||
| HGSC | |||||
| ccRCC | 0.166 | ||||
| GBM | -0.535 | ||||
| HNSC | -0.377 | ||||
| LUAD | -0.506 | ||||
| LUSC | 0.606 | ||||
| non_ccRCC | 2.493 | ||||
| PDAC | -0.926 | ||||
| UCEC | 0.191 | ||||
| MYCBP2-Ser183 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.876 | ||||
| COAD | -0.193 | ||||
| HGSC | |||||
| ccRCC | 0.16 | ||||
| GBM | -0.541 | ||||
| HNSC | -0.383 | ||||
| LUAD | -0.512 | ||||
| LUSC | 0.602 | ||||
| non_ccRCC | 2.49 | ||||
| PDAC | -0.933 | ||||
| UCEC | 0.186 | ||||
| MYCBP2-Ser2061 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MYCBP2-Ser2319 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.268 | ||||
| COAD | 0.094 | ||||
| HGSC | 2.875 | ||||
| ccRCC | -0.158 | ||||
| GBM | -0.15 | ||||
| HNSC | -0.451 | ||||
| LUAD | -0.041 | ||||
| LUSC | -0.033 | ||||
| non_ccRCC | -0.994 | ||||
| PDAC | -0.308 | ||||
| UCEC | -0.564 | ||||
| MYCBP2-Ser2353 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 2.183 | ||||
| HGSC | |||||
| ccRCC | 0.093 | ||||
| GBM | -1.324 | ||||
| HNSC | 0.006 | ||||
| LUAD | -0.034 | ||||
| LUSC | -1 | ||||
| non_ccRCC | -0.531 | ||||
| PDAC | 0.237 | ||||
| UCEC | 0.37 | ||||
| MYCBP2-Ser2681 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.72 | ||||
| ccRCC | |||||
| GBM | -0.996 | ||||
| HNSC | 0.762 | ||||
| LUAD | 0.953 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2687 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.694 | ||||
| HGSC | -1.476 | ||||
| ccRCC | 0.435 | ||||
| GBM | 0.479 | ||||
| HNSC | 0.156 | ||||
| LUAD | -0.626 | ||||
| LUSC | 1.243 | ||||
| non_ccRCC | -0.296 | ||||
| PDAC | 1.725 | ||||
| UCEC | -0.947 | ||||
| MYCBP2-Ser2741 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.209 | ||||
| GBM | |||||
| HNSC | -0.62 | ||||
| LUAD | -1.073 | ||||
| LUSC | |||||
| non_ccRCC | 1.429 | ||||
| PDAC | -0.56 | ||||
| UCEC | 1.033 | ||||
| MYCBP2-Ser2787 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.819 | ||||
| COAD | -1.111 | ||||
| HGSC | |||||
| ccRCC | 0.083 | ||||
| GBM | 1.468 | ||||
| HNSC | -0.15 | ||||
| LUAD | -0.288 | ||||
| LUSC | 0.827 | ||||
| non_ccRCC | |||||
| PDAC | 0.582 | ||||
| UCEC | 0.408 | ||||
| MYCBP2-Ser2789 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.309 | ||||
| COAD | -0.459 | ||||
| HGSC | 2.583 | ||||
| ccRCC | -0.065 | ||||
| GBM | 0.597 | ||||
| HNSC | -0.522 | ||||
| LUAD | -0.459 | ||||
| LUSC | 0.225 | ||||
| non_ccRCC | -0.703 | ||||
| PDAC | 0.13 | ||||
| UCEC | -0.017 | ||||
| MYCBP2-Ser2812 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.702 | ||||
| HGSC | 0.155 | ||||
| ccRCC | -1.492 | ||||
| GBM | 0.248 | ||||
| HNSC | -0.018 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 1.939 | ||||
| PDAC | 0.397 | ||||
| UCEC | -0.527 | ||||
| MYCBP2-Ser2832 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2833 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.383 | ||||
| HGSC | -1.258 | ||||
| ccRCC | |||||
| GBM | 1.503 | ||||
| HNSC | 0.063 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.075 | ||||
| MYCBP2-Ser2839 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.8 | ||||
| HGSC | -1.121 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.321 | ||||
| MYCBP2-Ser2844 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2871 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.273 | ||||
| COAD | -0.949 | ||||
| HGSC | 2.278 | ||||
| ccRCC | -0.119 | ||||
| GBM | -0.564 | ||||
| HNSC | -0.402 | ||||
| LUAD | -0.032 | ||||
| LUSC | 1.144 | ||||
| non_ccRCC | 0.426 | ||||
| PDAC | 0.044 | ||||
| UCEC | -0.552 | ||||
| MYCBP2-Ser2873 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.453 | ||||
| HGSC | 1.478 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.305 | ||||
| LUAD | -0.719 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2911 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2920 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.286 | ||||
| COAD | -0.83 | ||||
| HGSC | 1.009 | ||||
| ccRCC | -0.555 | ||||
| GBM | 2.236 | ||||
| HNSC | -0.47 | ||||
| LUAD | |||||
| LUSC | -1.036 | ||||
| non_ccRCC | 0.58 | ||||
| PDAC | -0.503 | ||||
| UCEC | -0.144 | ||||
| MYCBP2-Ser2930 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2985 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| MYCBP2-Ser342 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.865 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 1.095 | ||||
| LUAD | -0.229 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser3426 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser3478 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.205 | ||||
| HGSC | 1.554 | ||||
| ccRCC | |||||
| GBM | -0.615 | ||||
| HNSC | 1.15 | ||||
| LUAD | |||||
| LUSC | 0.034 | ||||
| non_ccRCC | -0.377 | ||||
| PDAC | -0.344 | ||||
| UCEC | -1.607 | ||||
| MYCBP2-Ser3505 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.528 | ||||
| COAD | 0.4 | ||||
| HGSC | 2.452 | ||||
| ccRCC | -0.586 | ||||
| GBM | -0.753 | ||||
| HNSC | 0.081 | ||||
| LUAD | 0.235 | ||||
| LUSC | 0.861 | ||||
| non_ccRCC | -0.296 | ||||
| PDAC | -0.953 | ||||
| UCEC | -0.915 | ||||
| MYCBP2-Ser3519 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.9 | ||||
| HGSC | 1.685 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.596 | ||||
| LUAD | -0.267 | ||||
| LUSC | -0.165 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.948 | ||||
| MYCBP2-Ser3931 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.456 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.891 | ||||
| GBM | -0.526 | ||||
| HNSC | -0.342 | ||||
| LUAD | 1.751 | ||||
| LUSC | 0.608 | ||||
| non_ccRCC | -1.652 | ||||
| PDAC | 0.312 | ||||
| UCEC | -0.585 | ||||
| MYCBP2-Ser3932 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.176 | ||||
| COAD | |||||
| HGSC | -1.779 | ||||
| ccRCC | 0.869 | ||||
| GBM | -0.515 | ||||
| HNSC | -0.088 | ||||
| LUAD | 1.536 | ||||
| LUSC | 0.649 | ||||
| non_ccRCC | -1.186 | ||||
| PDAC | 0.765 | ||||
| UCEC | -0.075 | ||||
| MYCBP2-Ser3944 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.635 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.518 | ||||
| LUSC | -1.153 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser899 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.776 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.802 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.503 | ||||
| LUSC | -0.444 | ||||
| non_ccRCC | |||||
| PDAC | 0.866 | ||||
| UCEC | 0.048 | ||||
| MYCBP2-Thr1625 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2058 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MYCBP2-Thr2344 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.636 | ||||
| GBM | |||||
| HNSC | 1.153 | ||||
| LUAD | -0.516 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2347 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2683 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.322 | ||||
| HGSC | 1.836 | ||||
| ccRCC | 0.059 | ||||
| GBM | -0.907 | ||||
| HNSC | 0.32 | ||||
| LUAD | -0.883 | ||||
| LUSC | 0.739 | ||||
| non_ccRCC | 0.557 | ||||
| PDAC | 0.295 | ||||
| UCEC | -1.695 | ||||
| MYCBP2-Thr2880 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr3508 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr3921 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| MYCBP2-Thr3943 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Tyr3477 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Tyr3484 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser352 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser355 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser361 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Thr58 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Ser115 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.766 | ||||
| HGSC | 1.131 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.365 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Ser129 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.033 | ||||
| HGSC | 0.388 | ||||
| ccRCC | 0.202 | ||||
| GBM | |||||
| HNSC | -0.325 | ||||
| LUAD | -0.216 | ||||
| LUSC | -1.956 | ||||
| non_ccRCC | |||||
| PDAC | 0.874 | ||||
| UCEC | |||||
| MYCT1-Ser135 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.542 | ||||
| COAD | 0.75 | ||||
| HGSC | 0.574 | ||||
| ccRCC | 0.064 | ||||
| GBM | 1.358 | ||||
| HNSC | 1.25 | ||||
| LUAD | -0.087 | ||||
| LUSC | -0.849 | ||||
| non_ccRCC | -0.867 | ||||
| PDAC | -1.066 | ||||
| UCEC | -1.67 | ||||
| MYCT1-Ser138 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 1.696 | ||||
| ccRCC | -0.48 | ||||
| GBM | |||||
| HNSC | -0.812 | ||||
| LUAD | 0.734 | ||||
| LUSC | -1.023 | ||||
| non_ccRCC | -1.043 | ||||
| PDAC | 0.718 | ||||
| UCEC | 0.209 | ||||
| MYCT1-Ser141 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.047 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 1.444 | ||||
| LUSC | -0.582 | ||||
| non_ccRCC | -1.196 | ||||
| PDAC | |||||
| UCEC | 0.381 | ||||
| MYCT1-Ser149 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.23 | ||||
| COAD | -0.234 | ||||
| HGSC | 2.256 | ||||
| ccRCC | 0.036 | ||||
| GBM | 0.337 | ||||
| HNSC | -0.079 | ||||
| LUAD | -0.751 | ||||
| LUSC | -0.325 | ||||
| non_ccRCC | -0.535 | ||||
| PDAC | -0.527 | ||||
| UCEC | -1.409 | ||||
| MYCT1-Ser155 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.233 | ||||
| HGSC | 1.679 | ||||
| ccRCC | -0.048 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.429 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.969 | ||||
| MYCT1-Thr143 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.567 | ||||
| ccRCC | 0.377 | ||||
| GBM | |||||
| HNSC | 1.004 | ||||
| LUAD | -0.413 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.535 | ||||
| MYCT1-Thr219 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Tyr116 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Tyr126 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | 0.351 |
| GBM | |
| HNSC | -1.128 |
| LUAD | 0.778 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 58 | A | T-cell acute lymphoblastic leukemia | Phosphorylation | 32049046 |
| - | - | A | T-cell acute lymphoblastic leukemia | Ubiquitination | 32049046 |
| S | 62 | A | Cancer | Phosphorylation | 32188705 |
| T | 58 | D | Papillary adenoma | Phosphorylation | 17192266 |
| T | 58 | D | Squamous cell carcinoma | Phosphorylation | 32895364 |
| S | 62 | D | Medulloblastoma | Phosphorylation | 36765089 |
| T | 58 | D | Triple-negative breast cancer | Phosphorylation | 33541412 |
| T | 58 | D | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 17192266 |
| T | 58 | D | Breast cancer/tumor/carcinoma | Phosphorylation | 17192266 |
| T | 58 | D | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 17192266 |
| T | 58 | D | Islet cell carcinoma | Phosphorylation | 17192266 |
| T | 58 | D | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 17192266 |
| T | 58 | D | Cancer | Phosphorylation | 36639831 |
| T | 58 | D | T-cell lymphoma | Phosphorylation | 17192266 |
| - | - | D | Non-small cell lung cancer | Ubiquitination | 35598017 |
| - | - | D | Esophageal squamous cell carcinoma | Ubiquitination | 35593463 |
| - | - | D | Bladder cancer | Ubiquitination | 37105989 |
| - | - | D | Colorectal cancer | Ubiquitination | 37212463 |
| - | - | D | Colorectal cancer | Ubiquitination | 32796813 |
| - | - | D | Osteosarcoma | Ubiquitination | 36803784 |
| T | 58 | D | Neuroblastoma | Phosphorylation | 37973789 |
| T | 58 | D | Breast cancer | Phosphorylation | 21808024 |
| T | 58 | D | AIDS-related lymphoma | Phosphorylation | 17310999 |
| T | 58 | D | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 10488335 |
| T | 58 | N | Cervical cancer/carcinoma | Phosphorylation | 15150404 |
| T | 58 | P | B-cell lymphoma | Phosphorylation | 10706881 |
| - | - | P | Cervical cancer/carcinoma | Ubiquitination | 15150404 |
| S | 62 | P | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 10488335 |
| S | 62 | P | Breast cancer/tumor/carcinoma | Phosphorylation | 22307329 |
| S | 62 | P | T-cell lymphoma | Phosphorylation | 10488335 |
| - | - | P | Breast cancer | Ubiquitination | 35296795 |
| - | - | P | Retinoblastoma | Ubiquitination | 34761308 |
| S | 67 | P | T-cell acute lymphoblastic leukemia | Phosphorylation | 32049046 |
| S | 373 | P | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 23550155 |
| S | 62 | P | Lung cancer | Phosphorylation | 33552953 |
| T | 58 | P | Burkitt lymphoma | Phosphorylation | 10713166 ; 10866684 |
| S | 67 | U | Cancer | Phosphorylation | 33461590 |
| - | - | U | Anaplastic thyroid cancer | Acetylation | 30400007 |
| T | 58 | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 10488335 ; 17192266 |
| T | 58 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 11175856 ; 17192266 |
| T | 58 | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 15455033 ; 17192266 |
| S | 62 | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 17192266 |
| S | 62 | U | B-cell lymphoma | Phosphorylation | 15095297 ; 17192266 |
| - | - | U | Hepatocellular carcinoma | Ubiquitination | 36481361 |
| - | - | U | Colorectal cancer | Ubiquitination | 34109174 |
| - | - | U | Triple-negative breast cancer | Ubiquitination | 36528490 |
| T | 58 | U | Islet cell carcinoma | Phosphorylation | 12015982 ; 17192266 |
| S | 62 | U | Chronic myelogenous leukemia/chronic myeloid leukemia | Phosphorylation | 16855632 |
| - | - | U | Gastric cancer | Ubiquitination | 35397617 |
| T | 58 | U | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 12098700 ; 17192266 |
| S | 71 | U | Cancer | Phosphorylation | 33461590 |
| S | 62 | U | T-cell lymphoma | Phosphorylation | 17192266 |
| T | 58 | U | Papillary adenoma | Phosphorylation | 10360173 ; 17192266 |
| S | 62 | U | Colorectal cancer | Phosphorylation | 35039060 |
| S | 62 | U | Breast cancer | Phosphorylation | 31944568 ; 21808024 |
| S | 62 | U | Hepatocellular carcinoma | Phosphorylation | 25893300 |
| T | 58 | U | T-cell lymphoma | Phosphorylation | 10488335 ; 17192266 |
| S | 62 | U | Squamous cell carcinoma | Phosphorylation | 32895364 |
| K | 148 | U | Hepatocellular carcinoma | Acetylation | 37739936 |
| Y | 74 | U | Ovarian cancer/carcinoma | Phosphorylation | 23318434 |
| S | 62 | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 15455033 ; 17192266 |
| S | 62 | U | Islet cell carcinoma | Phosphorylation | 17192266 ; 12015982 |
| S | 62 | U | Liver cancer | Phosphorylation | 34758313 |
| S | 62 | U | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 17192266 ; 12098700 |
| S | 62 | U | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
| S | 62 | U | Papillary adenoma | Phosphorylation | 17192266 ; 10360173 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
